Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

A logical first approach might be to target appropriate members of the Janus kinase (JAK) family or the signal transducers and activators of transcription (STAT) family, as these proteins are ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical ...

Janus kinase inhibitors (JAKis ... Because these drugs specifically block cellular signaling pathways that are responsible ...